Equities

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)126.67
  • Today's Change1.57 / 1.25%
  • Shares traded885.84k
  • 1 Year change+4.07%
  • Beta0.5699
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,626881591
Total Receivables, Net855743563
Total Inventory5977141,073
Prepaid expenses18592131
Other current assets, total172176252
Total current assets3,4352,6062,611
Property, plant & equipment, net235301343
Goodwill, net1,7531,6931,828
Intangibles, net5,4185,7947,152
Long term investments------
Note receivable - long term------
Other long term assets675541
Total assets11,39310,83512,299
LIABILITIES
Accounts payable10391100
Accrued expenses793803647
Notes payable/short-term debt000
Current portion long-term debt/capital leases6053131
Other current liabilities, total368.1830
Total current liabilities1,537933809
Total long term debt5,1135,6996,025
Total debt5,7185,7306,057
Deferred income tax8489441,301
Minority interest------
Other liabilities, total159173198
Total liabilities7,6567,7508,333
SHAREHOLDERS EQUITY
Common stock0.060.060.06
Additional paid-in capital3,7003,4773,535
Retained earnings (accumulated deficit)879734831
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(842)(1126)(400)
Total equity3,7373,0863,965
Total liabilities & shareholders' equity11,39310,83512,299
Total common shares outstanding626362
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.